ClinicalTrials.gov
ClinicalTrials.gov Menu

Hereditary Tubulointerstitial Nephritis (NTIH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01312727
Recruitment Status : Completed
First Posted : March 11, 2011
Last Update Posted : August 26, 2016
Sponsor:
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The aim of this study is to identify families with hereditary chronic tubulointerstitial renal diseases , characterize the phenotype and screen for mutations in known genesis (UMOD, REN, TCF2, NPHP1). Genome wide analysis will be performed in families without mutations identified.

Condition or disease Intervention/treatment Phase
Nephritis, Interstitial Chronic Renal Failure Gout Renal Cysts Other: Blood and urine sample collections Not Applicable

Detailed Description:
  • Inclusion of affected subjects with familial history of chronic renal failure, early gout ,renal cysts in several hospital in France
  • Characterization of the phenotype; dosage of the urinary uromodulin in all subjects
  • Collect DNA samples
  • Screen for UMO mutations first
  • Then for REN or TCF2 depending on the phenotype
  • Validate the use of the dosage of urinary uromodulin for the diagnosis of UMOD associated disease.
  • Identify new genes responsible for hereditary HTIN (Hereditary Tubulointerstitial Nephritis).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 225 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Phenotypical and Genetic Characterization of Adult Hereditary Chronic Tubulointerstitial Renal Diseases
Study Start Date : November 2010
Actual Primary Completion Date : February 2014
Actual Study Completion Date : July 2016

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Gout

Arm Intervention/treatment
HTIN
HTIN
Other: Blood and urine sample collections
phenotype and genotype analysis, biological analysis
Other Name: phenotype and genotype analysis, biological analysis




Primary Outcome Measures :
  1. Genotype of HTIN [ Time Frame: after 18 months ]
    Number of patients/families with mutations in known genes responsible for HTIN


Secondary Outcome Measures :
  1. Uromodulin dosage in urine [ Time Frame: at 18 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • HTIN of unknown cause
  • Chronic renal failure defined by a eGFR (estimated Glomerular Filtration Rate) estimated according to MDRD (Modification of the Diet in Renal Disease) < 60ml / min / 1,73m2.
  • At least two siblings affected by gout before 40 years or by chronic renal failure.
  • Affiliated or benefiting from a national insurance
  • Signature of the enlightened consent.

Exclusion Criteria:

  • Endstage renal failure before the age of 18 years in all affected subjects of the family.
  • Microscopic or macroscopic persistent hematuria, or proteinuria > 1gramme / 24hours.
  • Other potential cause of TIN (Tubulointerstitial Nephritis): pyelonephritis, drug toxicity.
  • High blood pressure known for more than 10 years before the discovery of the renal disease.
  • Major cardiovascular before the discovery of the renal disease.
  • Chronic auto-immune or infectious disease.
  • Polycystic kidney disease with increased of the size of the kidneys

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01312727


Locations
France
Hôpital Necker Enfants Malades
Paris, France, 75015
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Principal Investigator: Bertrand Knebelmann, MD, PhD Assistance Publique - Hôpitaux de Paris

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT01312727     History of Changes
Other Study ID Numbers: P081258
First Posted: March 11, 2011    Key Record Dates
Last Update Posted: August 26, 2016
Last Verified: January 2016

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Tubulointerstitial renal diseases
Hereditary renal diseases
Uromodulin
Renin gene

Additional relevant MeSH terms:
Renal Insufficiency
Nephritis
Kidney Failure, Chronic
Nephritis, Interstitial
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic